NewGenIvf Group (NASDAQ:NIVF) Rating Lowered to “Strong Sell” at Wall Street Zen

NewGenIvf Group (NASDAQ:NIVF) was downgraded by analysts at Wall Street Zen to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating. According to MarketBeat, NewGenIvf Group has an average rating of “Sell”.

NewGenIvf Group Stock Performance

NIVF stock opened at $1.46 on Friday. The company has a fifty day moving average of $23.43 and a 200-day moving average of $176.96. NewGenIvf Group has a one year low of $1.14 and a one year high of $22,636.80.

NewGenIvf Group (NASDAQ:NIVF) last issued its quarterly earnings results on Wednesday, October 7th. The company reported ($426.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $581.76 by ($1,008.00). The firm had revenue of $0.96 million for the quarter, compared to analyst estimates of $20.10 million. As a group, equities analysts anticipate that NewGenIvf Group will post 1365.44 earnings per share for the current fiscal year.

About NewGenIvf Group

NewGenIvf Group Limited is a reproductive-healthcare company focused on fertility treatment and assisted reproductive technology. Through its operating businesses, the company provides services intended to help individuals and couples pursue pregnancy, including in vitro fertilization (IVF) and related fertility-care procedures.

Its services may include fertility consultations, laboratory-based embryo procedures, intracytoplasmic sperm injection (ICSI), embryo transfer, fertility preservation, and genetic testing or screening associated with assisted reproduction.